Tumor microenvironment-responsive linker activation (TME linker activation)

Tumor microenvironment-responsive linker activation is a pharmacological strategy used to achieve site-specific drug release, primarily in the context of antibody-drug conjugates (ADCs) and prodrugs (Nature Reviews Drug Discovery, 2022). This mechanism relies on the distinct biochemical landscape of the tumor microenvironment (TME), which differs significantly from healthy tissue in terms of pH, enzymatic activity, and redox potential (Nature, 2017). Linkers are engineered to remain stable in systemic circulation but undergo rapid cleavage when exposed to TME-specific triggers such as acidic conditions or overexpressed proteases like cathepsin B and matrix metalloproteinases (MMPs). This targeted activation allows for the delivery of highly potent cytotoxic payloads directly to malignant cells, thereby increasing the therapeutic index and reducing systemic side effects (Journal of Medicinal Chemistry, 2020). Furthermore, extracellular activation can facilitate a 'bystander effect,' where the released payload diffuses to neighboring tumor cells that may not express the primary target antigen, enhancing efficacy in heterogeneous tumors. This approach is a cornerstone of modern precision oncology, enabling the clinical use of agents that are otherwise too toxic for conventional systemic delivery.

Other names

TME-triggered drug releaseExtracellular linker cleavageStimuli-responsive linker activationTumor-selective payload releaseConditional payload activation

Release of cytotoxic payloads through the selective cleavage of chemical linkers by tumor-specific stimuli such as acidic pH, overexpressed proteases (e.g., MMPs, cathepsins), or high glutathione levels.